State research center of Virology and biotechnology “Vector” begun clinical trials of a vaccine against COVID-19.

— the other day we received permission to conduct clinical trials of a vaccine against coronavirus. We started yesterday, the 27th, to conduct a phase I-II clinical trials, — TASS quoted the head of Rospotrebnadzor Anna Popova.

According to issued by on 24 July the Ministry resolution, a vaccine based on peptide antigens, “Apiversion” get 100 volunteers aged 18-60 years. It is known that it will be a suspension for intramuscular injection. The tests are carried out FGBUZ “Mediko-a sanitary part № 163 of the Federal medical-biological Agency” in Koltsovo.